Get the Stockscreener App
1.02
2.00%
0.02
Cytosorbents Corp stock is traded at $1.02, with a volume of 7,842.
It is up +2.00% in the last 24 hours and down -19.05% over the past month.
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
See More
Previous Close:
$1.00
Open:
$1.02
24h Volume:
7,842
Relative Volume:
0.07
Market Cap:
$63.86M
Revenue:
$33.79M
Net Income/Loss:
$-18.67M
P/E Ratio:
-2.8476
EPS:
-0.3582
Net Cash Flow:
$-19.17M
1W Performance:
-1.92%
1M Performance:
-19.05%
6M Performance:
-0.97%
1Y Performance:
-0.49%
1-Day Range:
$1.01
$1.0282
1-Week Range:
$0.99
$1.10
52-Week Range:
$0.7101
$1.61
Cytosorbents Corp Stock (CTSO) Company Profile
Name
Cytosorbents Corp
Sector
Industry
Phone
973-329-8885
Address
305 COLLEGE ROAD EAST, PRINCETON, NJ
Compare CTSO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTSO
Cytosorbents Corp
|
1.02 | 62.61M | 33.79M | -18.67M | -19.17M | -0.3582 |
|
ABT
Abbott Laboratories
|
125.83 | 218.75B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
107.76 | 152.62B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
400.93 | 151.01B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
92.01 | 117.43B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
76.91 | 44.76B | 5.54B | 4.18B | 623.10M | 7.00 |
Cytosorbents Corp Stock (CTSO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-07-23 | Initiated | B. Riley Securities | Buy |
| Oct-14-21 | Resumed | B. Riley Securities | Buy |
| Sep-17-20 | Initiated | Jefferies | Buy |
| Sep-01-20 | Initiated | SVB Leerink | Outperform |
| Aug-08-17 | Reiterated | Maxim Group | Buy |
| Oct-26-16 | Initiated | Aegis Capital | Buy |
| May-24-16 | Initiated | Maxim Group | Buy |
| Oct-29-15 | Upgrade | WBB Securities | Speculative Buy → Buy |
| May-12-15 | Reiterated | MLV & Co | Buy |
| Apr-01-15 | Reiterated | MLV & Co | Buy |
| Mar-05-15 | Initiated | MLV & Co | Buy |
| Feb-25-15 | Initiated | WBB Securities | Speculative Buy |
| Jan-27-15 | Reiterated | H.C. Wainwright | Buy |
View All
Cytosorbents Corp Stock (CTSO) Latest News
What analysts say about Cytosorbents Corporation stockUnmatched market performance - jammulinksnews.com
What drives Cytosorbents Corporation stock priceStrongest growth potential - jammulinksnews.com
Why Cytosorbents Corporation stock attracts strong analyst attentionBreakout Momentum Stocks - Newser
Cytosorbents (NASDAQ:CTSO) Given “Buy” Rating at D. Boral Capital - Defense World
CytoSorbents (CTSO) Stock Rating and Price Target Maintained by - GuruFocus
Is Cytosorbents Corporation a good long term investmentExtraordinary profit generation - jammulinksnews.com
What institutions are buying Cytosorbents Corporation stock nowLong Term Low Risk Growth - Newser
What makes Cytosorbents Corporation stock price move sharplyRisk Controlled Trading Ideas - Newser
Cytosorbents stock plunges after regulatory setbacks for key device - Investing.com
CytoSorbents provides FDA, Health Canada regulatory update for DrugSorb-ATR - TipRanks
Cytosorbents Provides U.S. FDA And Health Canada Regulatory Update For Drugsorb-Atr - TradingView
CytoSorbents receives FDA appeal hearing date for DrugSorb-ATR device - Investing.com
CytoSorbents Provides U.S. FDA and Health Canada Regulatory Update for DrugSorb-ATR - PR Newswire
Cytosorbents Corporation(NasdaqCM: CTSO) added to Russell Microcap Index - MarketScreener
CytoSorbents files appeal with FDA over denied device application - Investing.com
CytoSorbents Q1 2025 slides: Revenue dips 3% as company targets breakeven by year-end - Investing.com
Millennium Management LLC Buys Shares of 33,280 Cytosorbents Co. (NASDAQ:CTSO) - Defense World
Cytosorbents announces voting results from annual meeting By Investing.com - Investing.com Canada
Cytosorbents announces voting results from annual meeting - Investing.com
CytoSorbents Warrants Expire Worthless as Stock Price Fails Threshold - Investing.com
Cytosorbents Co. (NASDAQ:CTSO) Shares Purchased by Northern Trust Corp - Defense World
Critical Care Leader CytoSorbents Reveals Growth Strategy at Jefferies Healthcare Conference - Stock Titan
Cytosorbents Therapy Significantly Reduces Bleeding in Urgent CABG Patients on Ticagrelor in New Data Presented At EuroPCR 2025 - marketscreener.com
CytoSorbents device cuts bleeding in CABG patients - Investing.com
New Clinical Data: How CytoSorbents' Breakthrough Device Slashes Severe Bleeding Risk in Urgent Heart Surgery - Stock Titan
Cytosorbents (NASDAQ:CTSO) Coverage Initiated by Analysts at StockNews.com - Defense World
Cytosorbents FY2025 EPS Forecast Lifted by HC Wainwright - Defense World
D. Boral Capital Reiterates “Buy” Rating for Cytosorbents (NASDAQ:CTSO) - Defense World
Cytosorbents (NASDAQ:CTSO) Earns Neutral Rating from HC Wainwright - Defense World
Cytosorbents Corporation (NASDAQ:CTSO) Q1 2025 Earnings Call Transcript - Insider Monkey
Cytosorbents Corp’s Earnings Call: A Balanced Outlook - TipRanks
CytoSorbents (CTSO) Receives Neutral Rating from HC Wainwright & Co. | CTSO Stock News - GuruFocus
CytoSorbents (CTSO) Maintains Buy Rating with $10 Price Target | - GuruFocus
CytoSorbents (CTSO) Maintains Buy Rating with $10 Price Target | CTSO Stock News - GuruFocus
CytoSorbents: Q1 Earnings Snapshot - CT Insider
CytoSorbents Corp (CTSO) Q1 2025 Earnings Call Highlights: Navigating Challenges and ... - Yahoo Finance
CytoSorbents Corp (CTSO) Q1 2025 Earnings Call Highlights: Navigating Challenges and Strengthening Financials - GuruFocus
StockNews.com Initiates Coverage on Cytosorbents (NASDAQ:CTSO) - Defense World
CytoSorbents (CTSO) Targets Growth Amid Regulatory Challenges - GuruFocus
Earnings call transcript: CytoSorbents Q1 2025 misses earnings, stock dips - Investing.com
Cytosorbents Corp Stock (CTSO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):